Last €0.15 EUR
Change Today 0.00 / 0.00%
Volume 0.0
D7G On Other Exchanges
Symbol
Exchange
Oslo
Berlin
As of 2:06 AM 12/23/14 All times are local (Market data is delayed by at least 15 minutes).

diagenic asa (D7G) Snapshot

Open
€0.15
Previous Close
€0.15
Day High
€0.15
Day Low
€0.15
52 Week High
02/26/14 - €0.30
52 Week Low
12/27/13 - €0.06
Market Cap
60.6M
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
398.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for DIAGENIC ASA (D7G)

Related News

No related news articles were found.

diagenic asa (D7G) Related Businessweek News

No Related Businessweek News Found

diagenic asa (D7G) Details

DiaGenic ASA researches, develops, sells, and markets blood based gene expression tests. The company was founded in 1998 and is headquartered in Oslo, Norway.

11 Employees
Last Reported Date: 03/21/14
Founded in 1998

diagenic asa (D7G) Top Compensated Officers

Chief Financial Officer
Total Annual Compensation: 1.2M NOK
Compensation as of Fiscal Year 2013.

diagenic asa (D7G) Key Developments

DiaGenic ASA, Special/Extraordinary Shareholders Meeting, Dec 19, 2014

DiaGenic ASA, Special/Extraordinary Shareholders Meeting, Dec 19, 2014., at 10:00 Central European Standard Time. Location: Sjølyst Plass 2. Agenda: To consider the election of board members an remuneration of the board; to consider the election of members to the nomination committee and remuneration of the nomination committee; to consider the board authorization for share capital increase; to consider the share capital increase-private placement; and to consider the share capital increase-subsequent repair offering.

DiaGenic ASA Reports Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

DiaGenic ASA reported consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, operating loss was NOK 763,000 against NOK 9,505,000 a year ago. Pre-tax loss was NOK 480,000 against NOK 9,277,000 a year ago. Net loss was NOK 480,000 or NOK 0.00 per share after dilution against NOK 9,277,000 or NOK 1 per share after dilution a year ago. Net cash outflow from operating activities was NOK 1,058,000 against NOK 9,253,000 a year ago. For the nine months, operating loss was NOK 6,108,000 against NOK 30,381,000 a year ago. Pre-tax loss was NOK 5,496,000 against NOK 29,930,000 a year ago. Net loss was NOK 5,496,000 or NOK 0.00 per share after dilution against NOK 29,930,000 or NOK 5 per share after dilution a year ago. Net cash outflow from operating activities was NOK 9,002,000 against NOK 29,278,000 a year ago.

DiaGenic ASA, Q3 2014 Earnings Call, Nov 20, 2014

DiaGenic ASA, Q3 2014 Earnings Call, Nov 20, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
D7G:GR €0.15 EUR 0.00

D7G Competitors

Market data is delayed at least 15 minutes.

Company Last Change
DiaxonHit €0.59 EUR 0.00
View Industry Companies
 

Industry Analysis

D7G

Industry Average

Valuation D7G Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3,473.0x
Price/Book 2.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 15,186.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DIAGENIC ASA, please visit www.diagenic.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.